Loading…
Protalix BioTherapeutics, Inc. is projected to rise to $3.49 by 2027, a +47% move from its current price of $2.37. PLX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $2.33 | $2.37 | $2.42 | +0.11% |
| Aug 4 | $2.31 | $2.38 | $2.44 | +0.23% |
| Aug 5 | $2.30 | $2.38 | $2.46 | +0.34% |
| Aug 6 | $2.29 | $2.38 | $2.48 | +0.46% |
| Aug 7 | $2.28 | $2.38 | $2.49 | +0.57% |
| Aug 8 | $2.27 | $2.39 | $2.50 | +0.69% |
| Aug 9 | $2.27 | $2.39 | $2.52 | +0.80% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.27 | $2.39 | $2.52 | +0.80% |
| Week 2 | $2.24 | $2.41 | $2.59 | +1.61% |
| Week 3 | $2.22 | $2.43 | $2.65 | +2.42% |
| Week 4 | $2.21 | $2.45 | $2.71 | +3.24% |
| Week 5 | $2.20 | $2.47 | $2.77 | +4.07% |
| Week 6 | $2.19 | $2.49 | $2.82 | +4.90% |
| Week 7 | $2.19 | $2.51 | $2.87 | +5.74% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease.
It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases.
The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
PLX is a biotechnology stock in the healthcare sector with a current price of $2.27 and a market capitalization of $182.9M. It ranks 3627 by market cap among listed assets.
The stock trades near its short- and intermediate-term moving averages, with the SMA50 at $2.20 and the SMA200 at $2.22. The current trading setup shows a support at $2.02 and a resistance at $2.44.
The 30-day price range runs from $2.01 to $2.56, and the stock carries an annualized volatility of 30%. The near-term sentiment is bullish, consistent with a chart picture that supports gradual upside potential.
Looking ahead, the forecast projects a path of rising averages and higher price levels, extending through 2050, with the 2026 average targeted at $2.27 and multi-year upside reflected in later years.
A major floor 19.8% below — a decisive break under it would weaken the trend.
The nearest floor, 8.9% below — buyers have tended to step in here.
Price is pressing into resistance (3.0% away) — a breakout level to watch.
A major ceiling 9.8% above — clearing it would confirm fresh momentum.
Key PLX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PLX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.33 | Buy | $2.33 | Buy |
| MA 10 | $2.35 | Buy | $2.34 | Buy |
| MA 20 | $2.35 | Buy | $2.33 | Buy |
| MA 50 | $2.21 | Buy | $2.26 | Buy |
| MA 100 | $2.22 | Buy | $2.24 | Buy |
| MA 200 | $2.22 | Buy | $2.18 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 55.93 | Neutral |
| Stoch RSI (14) | 59.89 | Neutral |
| CCI (20) | 28.58 | Neutral |
| Williams %R (14) | -28.57 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | 1.72 | Buy |
| Bollinger %B (20,2) | 0.59 | Neutral |
| Stochastic %K (14) | 71.43 | Neutral |
| TRIX (15) | 0.31 | Buy |
| Awesome (5,34) | 0.04 | Buy |
| Ultimate (7,14,28) | 50.87 | Neutral |
| Momentum (10) | -0.01 | Sell |
| Aroon Osc (25) | 40.00 | Buy |
| Hull MA (9) | 2.29 | Buy |
| ADX (14) | 16.78 | Neutral |
| ATR (14) | 0.04 | Info |
The 30-day technical picture presents a bullish tilt with RSI at 50. The stock sits near its SMA50 of $2.20 and SMA200 of $2.22, giving a consolidated near-term technical backdrop.
Support is pegged at $2.02 and resistance at $2.44, defining a near-term trading band. The 30-day price range spans from $2.01 to $2.56, indicating modest volatility within the current setup.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.74 | $2.37 | $3.34 | 0% | Neutral | |
| $2.85 | $3.49 | $4.46 | +47% | Bullish | |
| $3.08 | $3.84 | $5.04 | +62% | Bullish | |
| $3.69 | $4.68 | $6.29 | +97% | Bullish | |
| $4.20 | $5.39 | $7.39 | +128% | Bullish | |
| $4.65 | $6.04 | $8.41 | +155% | Bullish | |
| $6.15 | $8.09 | $11.43 | +241% | Bullish | |
| $7.06 | $9.40 | $13.45 | +297% | Bullish | |
| $7.55 | $10.15 | $14.71 | +328% | Bullish | |
| $8.23 | $11.18 | $16.39 | +372% | Bullish | |
| $13.84 | $19.64 | $30.21 | +729% | Bullish | |
| $30.75 | $46.98 | $77.61 | +18.8x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.74 | $2.37 | $2.91 | +0.00% |
| September 2026 | $2.20 | $2.58 | $3.09 | +8.66% |
| October 2026 | $2.23 | $2.63 | $3.18 | +2.11% |
| November 2026 | $2.23 | $2.64 | $3.22 | +0.45% |
| December 2026 | $2.30 | $2.73 | $3.34 | +3.24% |
Click any year to see its month-by-month PLX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The PLX price prediction for 2026 points to an average of $2.37 (low $1.74, high $3.34) — a potential gain of 0% on today's $2.37. A consolidation phase looks the most probable path here.
In 2027, PLX is projected to trade between $2.85 and $4.46, averaging $3.49 — a potential gain of +47% from today's $2.37. That is up +47% on the projected 2026 average. Momentum favours further upside here.
Protalix BioTherapeutics, Inc.'s 2028 outlook centres on $3.84, within a $3.08 to $5.04 range. That is up +10% on the projected 2027 average. That marks a +62% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, PLX could reach as high as $6.29, with a base case around $4.68 and support toward $3.69 — roughly +97% from $2.37. Momentum favours further upside here.
Expect PLX to range from $4.20 to $7.39 through 2030. The $5.39 average target implies a +128% move from current prices. That is up +15% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The PLX price prediction for 2031 points to an average of $6.04 (low $4.65, high $8.41) — a potential gain of +155% on today's $2.37. Momentum favours further upside here.
In 2032, PLX is projected to trade between $6.15 and $11.43, averaging $8.09 — a potential gain of +241% from today's $2.37. That is up +34% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Protalix BioTherapeutics, Inc.'s 2033 outlook centres on $9.40, within a $7.06 to $13.45 range. That is up +16% on the projected 2032 average. That marks a +297% change versus current levels. Momentum favours further upside here.
By 2034, PLX could reach as high as $14.71, with a base case around $10.15 and support toward $7.55 — roughly +328% from $2.37. Buyers look set to stay in control over this stretch.
Expect PLX to range from $8.23 to $16.39 through 2035. The $11.18 average target implies a +372% move from current prices. That is up +10% on the projected 2034 average. Momentum favours further upside here.
The PLX price prediction for 2040 points to an average of $19.64 (low $13.84, high $30.21) — a potential gain of +729% on today's $2.37. Buyers look set to stay in control over this stretch.
In 2050, PLX is projected to trade between $30.75 and $77.61, averaging $46.98 — a potential gain of +18.8x from today's $2.37. That is up +139% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in PLX today (≈ 421.940928 PLX) could be worth
$19,820.93
+$18,820.93 (+1882%) by 2050 · US Dollar
Based on the average projected PLX price of $46.98 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PLXwould be worth at today's price.
$1,000 invested in PLX on Jul 31, 2025 (≈ 684.931489 PLX) would be worth
$1,623.29
+$623.29 (+62.3%) today · 1.62× · US Dollar
Based on a PLX entry price of $1.46 vs. today's $2.37.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.37 | $1,000 | +0.0% |
| 1 month ago | $2.3 | $1,030.43 | +3.0% |
| 3 months ago | $2.12 | $1,117.92 | +11.8% |
| 6 months ago | $2.6 | $911.54 | -8.8% |
| 1 year ago | $1.46 | $1,623.29 | +62.3% |
| All time (5.0y) ago | $1.58 | $1,500 | +50.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PLX forecast.
Our base-case forecast reaches $4.70 around 2030.
Implied market cap at $4.70: $378.69M
The multi-year forecast shows an uptrend in the average price from 2026 through 2050, with bullish sentiment across the later years.
For 2026, the forecast lists min $1.74, avg $2.27, max $3.18, with ROIPct 0 and sentiment NEUTRAL. By 2027 the avg rises to $3.28 and the max to $4.18 (min $2.69, ROI 44.6, sentiment BULLISH), and by 2028 to an avg $3.56 with a max $4.67 (min $2.87, ROI 57, sentiment BULLISH). By 2029 the avg is $4.30 and the max $5.75 (min $3.40, ROI 89.2, sentiment BULLISH), and by 2030 the avg reaches $4.88 with a max $6.64 (min $3.81, ROI 114.8, sentiment BULLISH).
The forecast continues with 2031 avg $5.38, 2032 avg $7.16, 2033 avg $8.25, 2034 avg $8.84, and 2035 avg $9.70, all with bullish sentiment and rising price targets, including 2032 max $10.05 and 2035 max $14.10. The trajectory extends to 2040 with avg $16.55 and max $25.24 (ROI 629.1, sentiment BULLISH), and to 2050 with avg $38.52 and max $62.97 (ROI 1597, sentiment BULLISH).
These figures imply a long-run upward drift in price with increasing upside potential, but they are estimates and not guarantees. The numbers reflect a modeled outlook under varying scenarios and should be considered alongside inherent investment risk.
Tap a question to reveal the answer.
2030 min $3.81, avg $4.88, max $6.64; ROI: 114.8; sentiment: BULLISH.
The forecast shows a neutral stance in 2026 (min $1.74, avg $2.27, max $3.18; ROI: 0; sentiment NEUTRAL) followed by bullish sentiment in 2027 and beyond, with rising averages and ROI figures such as 44.6 in 2027, 57 in 2028, 89.2 in 2029, 114.8 in 2030, and growth continuing through 2050 (e.g., ROI 1597).
2032 forecast lists max $10.05, with 2032 avg $7.16 and min $5.47.
Current price is $2.27 and market cap is $182.9M.
Sentiment: BULLISH; RSI 50; SMA50 $2.20; SMA200 $2.22; support $2.02; resistance $2.44; 30-day range $2.01 to $2.56.
Protalix BioTherapeutics, Inc. Community Discussion
0Share your Protalix BioTherapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.